Several factors including age, genetics, lifestyle, and family history, personal history of breast cancer, dense breast tissue, menstrual periods and menopause are responsible for the development of breast cancer.
Global Breast Cancer Antibodies Biomarkers & Clinical Trials Insight 2028 Report Highlights:
- Global Breast Cancer Antibodies Market Opportunity: > USD 15 Billion
- Breast Cancer Antibodies Clinical Trials Insight: > 150 Drugs In Trials
- Breast Cancer Biomarkers Sourced During Clinical Trials
- Breast Cancer Biomarkers Insight By Antibodies Classification
- Insight On Biomarkers Sourced From Trials By Drugs & Indication
- Biomarker Name & Function Insight By Antibody
- Biomarker Insight Based On Drugs In Multiple Trials Phase & Multiple Indication
Download Report: https://www.kuickresearch.com/ccformF.php?t=1646994975
Breast cancer is one of the most frequently occurring cancers in women. Several factors including age, genetics, lifestyle, and family history, personal history of breast cancer, dense breast tissue, menstrual periods and menopause are responsible for the development of breast cancer. Traditionally, the management of breast cancer was mainly done by conventional cancer therapies including chemotherapy, hormonal therapy, radiotherapy and surgery. However, better understanding about the breast cancer biology has led to development of several novel targeted therapies with improved survival outcomes.
The arrival of new era of genomics, particularly high-throughput screening and identification of human genes has allowed for the development of new opportunities in the field of breast cancer research. Recently, antibody drug conjugates have also gained considerable popularity in the management of several subtypes of breast cancer. Kadcyla was the first ADC which entered the market. Further, Enhertu also gained approval which has shown enhanced efficiency in comparison to Kadcyla in targeting breast cancer. More recently, Trodelvy (sacituzumab govitecan) developed by Gilead Sciences has also granted US FDA approval for adult patients with unresectable locally advanced or metastatic TNBC who have received two or more prior therapies.
The entrance of antibodies in the management of cancer has shown high adoption rates in the global market which has further propelled the research and development activities in this region. The pharmaceutical companies are actively investing in this segment which has led to development of robust clinical pipeline of drugs which is expected to gain approval during the forecast period. For instance in 2022, US FDA has granted breakthrough therapy designation to Patritumab deruxtecan (U3-1402), a potential first-in-class HER3 directed antibody-drug conjugate. Apart from this, Ambrx Biopharma has also dosed he first subject in its global Phase II clinical trial of an advanced internal candidate, ARX788, in HER2-positive metastatic breast cancer patients.
The majority key players in market such as Pfizer, Amgen, Novartis, Eli Lilly, AstraZeneca, Sanofi, Bristol-Myers Squibb and others are contributing in the growth of market by bringing new ideas in treatment options of the breast cancer. The researchers are potentially utilizing the advancement in science and technology for the better understanding in the development and progression of disease and to identify potential therapeutic targets for drug development. Apart from this, several pharmaceutical giants have entered into collaboration or partnerships to maintain their position in market. For instance, Antengene entered into research collaboration with LegoChem Biosciences for the development of new antibody drug conjugates. Further, Gilead Sciences also collaborated with Merck to evaluate Trodelvy in combination with Keytruda in patients with first line triple negative breast cancer.
Currently, breast cancer is holding a major segment in the global antibody drug market owing to large number of product approvals and surge in prevalence of breast cancer. In 2021, breast cancer antibody constituted more than 20% of the global antibody market. The coming years is expected to witness dominance of this segment which can be justified by strong clinical pipeline, lack of competition from biosimilar drugs, and expanded approval in various subtypes of breast cancer.
As per our report findings, the global Breast Cancer Antibodies market will surpass US$ 15 Billion by 2028. The increasing prevalence of cancer is expected to be one of the key factors driving the growth of market during forecast period. In addition, major advancements in linker technology coupled with an increasing investment in research and development will further propel the growth of market. The report gives comprehensive analysis on the approved drugs patent, price and sales insight 2020 Till 2028 and ongoing clinical trials assessment by status, phase, and region.
Contact:
Neeraj Chawla
Research Head
Kuick Research
+91-9810410366